The research study will be conducted in adult subjects with relapsing forms of multiple sclerosis for which the decision to prescribe LEMTRADA has been made. The purpose of study is to further characterize the safety profile of LEMTRADA by systematic observation of vital signs during and shortly after LEMTRADA infusions of the first treatment course. Patient participation will last for approximately 2 to 7 week.
Who may be Eligible
Adults patients diagnosed with relapsing multiple sclerosis who are planning treatment with LEMTRADA.